Cost-and Risk-Benefit considerations in the management of clinical stage I nonseminomatous testicular tumors

Annals of Surgical Oncology

Volumn 3, Issue 1, 1996, Pages 86-93

  Baniel, Jack ^a   Roth, Bruce J ^a   Foster, Richard S ^a,b   Donohue, John P ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b University of Hospital   (United States)

Author keywords

Complications; Cost benefit analysis; Late relapse fertility; Management; Nonseminomatous germ cell tumors; Risk benefit analysis; Testis cancer

Indexed keywords

ARTICLE; CANCER STAGING; COST BENEFIT ANALYSIS; ECONOMICS; FOLLOW UP; HEALTH CARE COST; HUMAN; MALE; MALE INFERTILITY; MORBIDITY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SURVIVAL RATE; TESTIS TUMOR; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INFERTILITY, MALE; MALE; MORBIDITY; NEOPLASM STAGING; RISK ASSESSMENT; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SURVIVAL RATE; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0029690762     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02409057     Document Type: Article

References (31)

1. Freedman LS, Parkinson CM, Jones WAG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 1987;2:294-8.
2. Pont J, Hoeltl W, Kosak D, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 1990;8:16-20.
3. Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990;8:509-18.
4. Sesterhenn IA, Weiss RB, Mostofi FK, et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup. J Clin Oncol 1992;10:69-78.
5. Moul JW, McCarthy WF, Fernandez EB, Sesterhenn IA. Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. Cancer Res 1994;54:362-4.
6. de Riese WT, de Riese C, Ulbright TM, et al. Flow cytometric and quantitative histological parameters as prognostic indicators for occult retroperitoneal disease in clinical stage I nonseminomatous testicular germ cell tumors (NS-GCT). Int J Cancer 1994;57:628-33.
7. Moul JW, Foley JP, Hitchcock CL, et al. Flow cytometry and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 1993;150:879-83.
8. Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of the optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors. A Southeastern Cancer Study Group protocol. J Clin Oncol 1989;7:387-91.
9. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage I non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-1989. Br J Urol 1993;71:326-35.
10. Donohue JP, Zachary JM, Maynard SD. Distribution of nodal metastases in non-seminomatous testicular cancer. J Urol 1982;128:315-20.
11. Ray B, Hadju SI, Whitmore WF Jr. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 1974;33:340-8.
12. Sternberg C. Role of primary chemotherapy in stage I and low volume stage II non-seminomatous germ cell testis tumors. Urol Clin North Am 1993;20:93-109.
13. Lowe BA. Surveillance versus nerve-sparing retroperitoneal lymphadenectomy in stage I non-seminomatous germ cell tumors. Urol Clin North Am 1993;20:75-83.
14. Doubilet P, Weinstein MC, McNeal BJ. Use and misuse of the term "cost-effectiveness" in medicine. N Engl J Med 1986;314:253-6.
15. Skinner DG, Leadbetter WF. The surgical management of testis tumors J Urol 1971;106:84-93.
16. McCleod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the testicular cancer intergroup study. J Urol 11991;45:1178-83.
17. Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intra-operative stage I non-seminomatous germinal testis cancer. J Urol 1985;134:485-9.
18. Fung C, Kalish LA, Brodsky GL, Richie JP, Garnick MB. Stage I non-seminomatous germ cell tumor: prediction of metastatic potential by primary histopathology. J Clin Oncol 1988;6:1467-73.
19. Staubitz WJ, Early MS, Magoss IV, Murphy GP. Surgical management of testis tumor J Urol 1974;111:205-9.
20. Bredael J, Vugrin D, Whitmore WF. Recurrences in surgical stage I non-seminomatous germ cell tumors of the testis. J Urol 1983;130:476-8.
21. Sogani PC, Whitmore WF, Herr HW, et al. Orchiectomy alone in the treatment of clinical stage I non-seminomatous germ cell tumor of the testis. J Clin Oncol 1984;2:267-70.
22. Pizzocaro G, Zanoni F, Milani A, et al. Orchiectomy alone in clinical stage I non-seminomatous testis cancer: a critical appraisal. J Clin Oncol 1986;4:35-40.
23. Hoskin P, Duly S, Easton D, Horwich A, Hendry W, Peckham MJ. Prognostic factors in stage I non-seminomatous germ cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986;4:1031-6.
24. Read G, Stenning SP, Cullen MH, et al. Medical research council prospective study of surveillance for stage I testicular teratoma. Medical research council testicular tumor working party. J Clin Oncol 1992;10:1762-8.
25. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I non-seminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 1988;6:1597-603.
26. Raghavan D, Colls B, Levy J, et al. Surveillance for stage I non-seminomatous germ cell tumors of the testis the optimal protocol has not yet been defined. Br J Urol 1988;61:522-6.
27. Dunphy C, Ayala AG, Swanson DA, Ro JY, Logothetis C. Clinical stage I non-seminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a protocol after orchiectomy alone. Cancer 1988;62: 1202-6.
28. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Gierksky RE. Is postchemotherapy retroperitoneal surgery necessary in patients with non-seminomatous testicular cancer and minimal residual tumor. J Clin Oncol 1992;10:569-73.
29. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testicular cancer. J Urol 1987;137:1176-9.
30. Pizzocaro G, Salvioni R, Pasi M, et al. Early resection of residual tumor during cisplatin, vinblastine, bleomycin combination chemotherapy in stage 111 and bulky stage II non-seminomatous testicular cancer. Cancer 1985;56:249-55.
31. Jansen RLH, Sylvester R, Sleyfer DT, et al. Long term follow up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. Eur J Cancer 1991;27:695-8.